| Identification | Back Directory | [Name]
CNX-2006 | [CAS]
1375465-09-0 | [Synonyms]
CS-1000
CNX-2006
CNX-2006, >=98%
CNX2006; CNX 2006
CNX-2006 USP/EP/BP
N-(3-((2-((4-((1-(2-Fluoroethyl)azetidin-3-yl)amino)-2-methoxyphenyl)amino)-5-(trifluoromethyl
N-[3-[[2-[4-[[1-(2-fluoroethyl)azetidin-3-yl]amino]-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide
N-(3-((2-((4-((1-(2-Fluoroethyl)azetidin-3-yl)amino)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide
N-[3-({2-[(4-{[1-(2-Fluoroethyl)-3-azetidinyl]amino}-2-methoxyphe nyl)amino]-5-(trifluoromethyl)-4-pyrimidinyl}amino)phenyl]acrylam ide
N-[3-[[2-[[4-[[1-(2-Fluoroethyl)-3-azetidinyl]aMino]-2-Methoxyphenyl]aMino]-5-(trifluoroMethyl)-4-pyriMidinyl]aMino]phenyl]-2-propenaMide
2-Propenamide, N-[3-[[2-[[4-[[1-(2-fluoroethyl)-3-azetidinyl]amino]-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-
N-[3-[[2-[[4-[[1-(2-Fluoroethyl)-3-azetidinyl]amino]-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-2-propenamide CNX 2006
CNX 2006 N-[3-[[2-[[4-[[1-(2-Fluoroethyl)-3-azetidinyl]amino]-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-2-propenamide | [Molecular Formula]
C26H27F4N7O2 | [MDL Number]
MFCD26142654 | [MOL File]
1375465-09-0.mol | [Molecular Weight]
545.532 |
| Chemical Properties | Back Directory | [density ]
1.396±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20° C | [solubility ]
DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml; Ethanol: 10 mg/ml | [form ]
A crystalline solid | [pka]
13.23±0.70(Predicted) |
| Hazard Information | Back Directory | [Uses]
N-[3-[[2-[[4-[[1-(2-Fluoroethyl)-3-azetidinyl]amino]-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-2-propenamide, is a novel irreversible mutant-selective EGFR inhibitor. |
|
|